Celyad Oncology SA

ACTIVE

60 Broad St Ste 3502, New York City, New York, United Stateswww.celyad.comPublic51–100 employeesEstablished: 2007-01-01

Also known as:

clyyf

CYADY

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2007

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

76.9%

Phase 3

15.4%

Phase 2

7.7%

Trial Status Distribution

Active, not recruiting

7.7%

Completed

30.8%

Recruiting

23.1%

Terminated

7.7%

Unknown

23.1%

Withdrawn

7.7%

Clinical Trials

Trials sponsored by this organization (13)

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Phase 1

Recruiting

interventional

Nov 202134 participants

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

interventional

Nov 202018 participants

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

Phase 1

Recruiting

interventional

Nov 201927 participants

EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Phase 1

Recruiting

interventional

Nov 201849 participants

DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2

Phase 1

Completed

interventional

Sep 201821 participants

Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer

Phase 1

Terminated

interventional

Oct 20171 participant

Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases

Phase 1

Unknown

interventional

Aug 201736 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations